Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 210 results for "julie masow"

Vaccine manufacturer Novartis likely not to benefit from emerg...

Novartis spokeswoman Julie Masow said the company has filed an Investigational New Drug application with the FDA, although it has yet to reach an agreement with the agency on a pathway to licensure. Under the just-announced vaccination plan, ... Individual.com, 1 month ago

Novartis : Lays Off 75 Employees At Lincoln Plant

Novartis spokeswoman Julie Masow said that the layoffs were the third phase of a plan the company announced in April 2013 to reduce production at the facility and eliminate around 40% of jobs. The company, following the U.S. Food and Drug ...
 4 Traders1 month ago

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1) Signifor LAR, a next-generation somatostatin analog, provides a new option for patients with acromegaly with inadequately ...
 SearchBug3 days ago Novartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients  SearchBug1 month ago Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies  Franklin Credit Management Corporation1 month ago Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014  Digital Journal1 month ago
[x]  

Six-year pivotal study data reinforce the superiority of Tasigna® over Gleevec® in newly-diagnosed patients with Ph+ CML

EAST HANOVER, N.J., Dec. 8, 2014 /PRNewswire/ -- Six-year results from the randomized Phase III ENESTnd study continue to demonstrate the superiority of Tasigna (nilotinib) compared to Gleevec (imatinib mesylate)[*] at achieving higher rates of ...
 BusinessWeek1 week ago
[x]  

NOVARTIS : To Reduce Workforce In East Hanover

Novartis had announced in October 2014 that the company realigned its business units, forming a cardiovascular field force from its team focused on primary care. Novartis spokeswoman Julie Masow said that however, the company's anticipated needs ...
 4 Traders1 week ago

Novartis lays off 200 primary care reps as it preps for megablockbuster LCZ696 rollout

Even a megablockbuster launch isn't enough to save Novartis ($NVS) sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly ...
 FiercePharma1 week ago

Novartis AG Eliminating Up To 200 Jobs At U.S. Headquarters

Novartis Pharmaceuticals Corporation is eliminating as many as 200 jobs in East Hanover as part of a restructuring. In October, the Swiss drugmaker said, it realigned its business units, creating what it calls a cardiovascular field force from its ...
 BioSpace1 week ago

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia

EAST HANOVER, N.J. , Dec. 6, 2014 /PRNewswire/ --Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia.
 SearchBug1 week ago
[x]  

Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014

EAST HANOVER, N.J., Dec. 2, 2014 /PRNewswire/ -- Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and ...
 Financial Content2 weeks ago
[x]  

Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually

EAST HANOVER, N.J. , Nov. 18, 2014 /PRNewswire/ --A new global survey of more than 10,000 adults in 10 countries finds that a large majority of the general public feel they know little or nothing about lung cancer (84%), a devastating disease that ...
 Tamar Securities1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less